Spots Global Cancer Trial Database for alpelisib
Every month we try and update this database with for alpelisib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients | NCT04300790 | Breast Cancer | Alpelisib Metformin Fulvestrant Letrozole Exemestane Vildagliptin Tamoxifen | 18 Years - | MedSIR | |
| Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer. | NCT05230810 | HER2-positive M... | Alpelisib Tucatinib Fulvestrant | 18 Years - | Criterium, Inc. | |
| Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study. | NCT04852081 | Breast Cancer S... | Palbociclib Ribociclib Abemaciclib Letrozole Anastrozole Tamoxifen Fulvestrant Exemestane Alpelisib | 18 Years - | Blokhin's Russian Cancer Research Center | |
| Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation | NCT04208178 | Advanced HER2+B... | Alpelisib Alpelisib match... Trastuzumab Pertuzumab | 18 Years - | Novartis | |
| Managed Access Program to Provide Alpelisib for Patients With HR+ Advanced or Metastatic Breast Cancer | NCT03706573 | HR+ Advanced or... | alpelisib | 18 Years - | Novartis | |
| Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies | NCT02620839 | Solid Tumors | Alpelisib Cisplatin | 18 Years - | University of California, San Francisco | |
| Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer | NCT04524000 | Advanced Breast... | Alpelisib Fulvestrant | 18 Years - | Novartis | |
| Umbrella Trial Testing Integrative Subtype Targeted Therapeutics in Estrogen Receptor Positive, HER2-Negative Breast Cancer | NCT05101564 | Breast Cancer HER2-negative B... ER Positive Bre... | Alpelisib Tamoxifen Zotatifin Fulvestrant | 18 Years - | Stanford University | |
| Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer | NCT04544189 | Breast Neoplasm... | Alpelisib Fulvestrant Placebo | 18 Years - | Novartis | |
| Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss | NCT04251533 | Triple Negative... | alpelisib placebo nab-paclitaxel | 18 Years - | Novartis | |
| A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations | NCT05983159 | Slow-Flow Vascu... Fast-Flow Vascu... Vascular Malfor... Venous Malforma... Lymphatic Malfo... Lymphatic Malfo... Lymphangioma Arteriovenous M... Venous Malforma... Cystic Hygroma Vascular Anomal... Vascular Anomal... PI3K Gene Mutat... MAP2K1 Gene Mut... PIK3CA-related ... Arteriovenous M... KRAS G12C KRAS G12D | Alpelisib Mirdametinib | 2 Years - | Murdoch Childrens Research Institute | |
| Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer | NCT03601507 | CDKN2A-p16 Posi... HPV Positive Or... Stage I Orophar... Stage II Oropha... Stage III Oroph... Stage IVA Oroph... | Alpelisib Laboratory Biom... Pharmacodynamic... Therapeutic Con... | - | University of Arizona | |
| Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. | NCT02437318 | Breast Cancer | Fulvestrant Alpelisib Alpelisib place... | 18 Years - | Novartis | |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | NCT05564377 | Advanced Malign... Anatomic Stage ... Anatomic Stage ... Locally Advance... Malignant Femal... Metastatic HER2... Metastatic Mali... Recurrent Endom... Recurrent Fallo... Recurrent Malig... Recurrent Malig... Recurrent Ovari... Recurrent Prima... Unresectable HE... Unresectable Ma... | Alpelisib Binimetinib Biopsy Biospecimen Col... Bone Marrow Asp... Bone Scan Computed Tomogr... Echocardiograph... Fluorouracil Fulvestrant Ipatasertib Leucovorin Magnetic Resona... Multigated Acqu... Mutation Carrie... Neratinib Malea... Nilotinib Hydro... Olaparib Oxaliplatin Paclitaxel Palbociclib Panitumumab Positron Emissi... Selumetinib Sul... Sotorasib | - | National Cancer Institute (NCI) | |
| Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas | NCT03631953 | Meningioma | Trametinib Alpelisib Blood sample MRI | 18 Years - | Assistance Publique Hopitaux De Marseille | |
| Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies | NCT02620839 | Solid Tumors | Alpelisib Cisplatin | 18 Years - | University of California, San Francisco | |
| Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer | NCT03284957 | Breast Cancer | Amcenestrant Palbociclib Alpelisib Everolimus Abemaciclib | 18 Years - | Sanofi | |
| Managed Access Program to Provide Alpelisib for Patients With HR+ Advanced or Metastatic Breast Cancer | NCT03706573 | HR+ Advanced or... | alpelisib | 18 Years - | Novartis | |
| Compassionate Use of BYL 719 Alpelisib | NCT03941782 | Lymphangioma | Alpelisib | 18 Years - | New Mexico Cancer Care Alliance | |
| Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib | NCT05625087 | Breast Cancer S... | Alpelisib Ribociclib | 18 Years - | UNICANCER | |
| Managed Access Program to Provide Access to Alpelisib for Patients With Advanced Breast Cancer | NCT04473040 | HR+, HER2-, Adv... | alpelisib | 18 Years - 99 Years | Novartis | |
| Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations | NCT04216472 | Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Refractory Brea... Triple-Negative... | Alpelisib Nab-paclitaxel | 18 Years - | M.D. Anderson Cancer Center | |
| Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer | NCT03284957 | Breast Cancer | Amcenestrant Palbociclib Alpelisib Everolimus Abemaciclib | 18 Years - | Sanofi | |
| SAFIR-PI3K A Phase II Randomized Maintenance Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy in PIK3CA Mutated Advanced Breast Cancer | NCT03386162 | Breast Cancer, ... | Alpelisib Chemotherapy | 18 Years - | UNICANCER | |
| First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors | NCT05768139 | Breast Cancer Gynecologic Can... HNSCC Solid Tumors, A... | STX-478 Fulvestrant | 18 Years - | Scorpion Therapeutics, Inc. | |
| Alpelisib and Paclitaxel in PIK3CA-altered Gastric Cancer | NCT04526470 | Solid Tumor Stomach Cancer | Alpelisib Paclitaxel | 20 Years - | Seoul National University Bundang Hospital | |
| A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer | NCT05966584 | Breast Cancer | Benralizumab fulvestrant or ... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. | NCT02437318 | Breast Cancer | Fulvestrant Alpelisib Alpelisib place... | 18 Years - | Novartis | |
| Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer | NCT04762979 | Hormone Recepto... HER2-negative B... PIK3CA Mutant M... | Alpelisib Fulvestrant Aromatase inhib... | 18 Years - | Big Ten Cancer Research Consortium | |
| A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations | NCT05983159 | Slow-Flow Vascu... Fast-Flow Vascu... Vascular Malfor... Venous Malforma... Lymphatic Malfo... Lymphatic Malfo... Lymphangioma Arteriovenous M... Venous Malforma... Cystic Hygroma Vascular Anomal... Vascular Anomal... PI3K Gene Mutat... MAP2K1 Gene Mut... PIK3CA-related ... Arteriovenous M... KRAS G12C KRAS G12D | Alpelisib Mirdametinib | 2 Years - | Murdoch Childrens Research Institute | |
| Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers | NCT02734615 | Advanced or Met... | LSZ102 LEE011 BYL719 | 18 Years - | Novartis | |
| Alpelisib and Paclitaxel in PIK3CA-altered Gastric Cancer | NCT04526470 | Solid Tumor Stomach Cancer | Alpelisib Paclitaxel | 20 Years - | Seoul National University Bundang Hospital | |
| Utilizing Continuous Glucose Monitoring to Characterize and Manage Hyperglycemia in Patients Initiating Alpelisib | NCT06083038 | Metastatic Brea... | Alpelisib FreeStyle Libre... | 18 Years - | HealthPartners Institute | |
| Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant | NCT04899349 | Breast Cancer | Alpelisib Fulvestrant Metformin XR Dapagliflozin +... Dapagliflozin | 18 Years - | Novartis | |
| Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer | NCT05563220 | Breast Cancer Metastatic Brea... | Elacestrant Alpelisib Everolimus Ribociclib Palbociclib Capivasertib Abemaciclib | 18 Years - | Stemline Therapeutics, Inc. | |
| Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET) | NCT05063786 | Advanced Breast... | Trastuzumab Alpelisib Fulvestrant Vinorelbine Capecitabine Eribulin | 18 Years - | Spanish Breast Cancer Research Group | |
| Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss | NCT04251533 | Triple Negative... | alpelisib placebo nab-paclitaxel | 18 Years - | Novartis | |
| Utilizing Continuous Glucose Monitoring to Characterize and Manage Hyperglycemia in Patients Initiating Alpelisib | NCT06083038 | Metastatic Brea... | Alpelisib FreeStyle Libre... | 18 Years - | HealthPartners Institute | |
| Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) | NCT04997902 | HNSCC | Tipifarnib Alpelisib | 18 Years - | Kura Oncology, Inc. | |
| Umbrella Trial Testing Integrative Subtype Targeted Therapeutics in Estrogen Receptor Positive, HER2-Negative Breast Cancer | NCT05101564 | Breast Cancer HER2-negative B... ER Positive Bre... | Alpelisib Tamoxifen Zotatifin Fulvestrant | 18 Years - | Stanford University | |
| The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy | NCT04591431 | Breast Cancer Gastrointestina... Non Small Cell ... Other Cancer | Erlotinib Trastuzumab Trastuzumab emt... Pertuzumab Lapatinib Everolimus Vemurafenib Cobimetinib Alectinib Brigatinib Palbociclib Ponatinib Vismogedib Itacitinib Ipatasertib Entrectinib Atezolizumab Nivolumab Ipilimumab Pemigatinib Oncology Drugs Pralsetinib Selpercatinib Talazoparib Tepotinib Alpelisib | 18 Years - | Fondazione per la Medicina Personalizzata | |
| Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET) | NCT05063786 | Advanced Breast... | Trastuzumab Alpelisib Fulvestrant Vinorelbine Capecitabine Eribulin | 18 Years - | Spanish Breast Cancer Research Group | |
| Phase 1b Combo w/ Ribociclib and Alpelisib | NCT05508906 | Metastatic Brea... Advanced Breast... HR-positive Bre... HER2-negative B... | OP-1250 Ribociclib Alpelisib | 18 Years - | Olema Pharmaceuticals, Inc. | |
| Umbrella Trial Testing Integrative Subtype Targeted Therapeutics in Estrogen Receptor Positive, HER2-Negative Breast Cancer | NCT05101564 | Breast Cancer HER2-negative B... ER Positive Bre... | Alpelisib Tamoxifen Zotatifin Fulvestrant | 18 Years - | Stanford University | |
| A Post Marketing Surveillance on Piqray in Korea | NCT05293470 | Breast Cancer | Piqray | 18 Years - | Novartis | |
| A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy | NCT05646862 | Breast Cancer | Inavolisib Fulvestrant Alpelisib | 18 Years - | Hoffmann-La Roche | |
| Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations | NCT04216472 | Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Refractory Brea... Triple-Negative... | Alpelisib Nab-paclitaxel | 18 Years - | M.D. Anderson Cancer Center | |
| Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients | NCT04300790 | Breast Cancer | Alpelisib Metformin Fulvestrant Letrozole Exemestane Vildagliptin Tamoxifen | 18 Years - | MedSIR | |
| Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study. | NCT04852081 | Breast Cancer S... | Palbociclib Ribociclib Abemaciclib Letrozole Anastrozole Tamoxifen Fulvestrant Exemestane Alpelisib | 18 Years - | Blokhin's Russian Cancer Research Center | |
| Utilizing Continuous Glucose Monitoring to Characterize and Manage Hyperglycemia in Patients Initiating Alpelisib | NCT06083038 | Metastatic Brea... | Alpelisib FreeStyle Libre... | 18 Years - | HealthPartners Institute | |
| SMMART Adaptive Clinical Treatment (ACT) Trial | NCT05238831 | Advanced Breast... Advanced Malign... Advanced Ovaria... Advanced Pancre... Advanced Prosta... Advanced Sarcom... Anatomic Stage ... Anatomic Stage ... Recurrent Adult... Recurrent Breas... Recurrent Ovari... Recurrent Prost... Stage II Pancre... Stage III Ovari... Stage III Pancr... Stage IV Ovaria... Stage IV Pancre... | Alectinib Alpelisib Anastrozole Atezolizumab Bevacizumab Biopsy Biospecimen Col... Capecitabine Carboplatin Cobimetinib Entrectinib Eribulin Fulvestrant Hyaluronidase-z... Irinotecan Letrozole Nab-paclitaxel Niraparib Olaparib Paclitaxel Palbociclib Pertuzumab Quality-of-Life... Trastuzumab Trastuzumab Emt... Vemurafenib Vinorelbine Vismodegib | 18 Years - | OHSU Knight Cancer Institute | |
| Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant | NCT04899349 | Breast Cancer | Alpelisib Fulvestrant Metformin XR Dapagliflozin +... Dapagliflozin | 18 Years - | Novartis | |
| Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma | NCT05472220 | Solid Tumors, A... PIK3CA Mutation... PIK3CA Mutation Human Papilloma... HPV-Related Squ... Human Papilloma... Locally Advance... Metastatic Mali... | Alpelisib Carboplatin Hyperpolarized ... Continuous Gluc... | 18 Years - | University of California, San Francisco | |
| A Post Marketing Surveillance on Piqray in Korea | NCT05293470 | Breast Cancer | Piqray | 18 Years - | Novartis | |
| Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations | NCT04216472 | Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Refractory Brea... Triple-Negative... | Alpelisib Nab-paclitaxel | 18 Years - | M.D. Anderson Cancer Center | |
| Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study | NCT04801966 | Cancer | Trametinib Cobimetinib Binimetinib Alpelisib Vemurafenib Dabrafenib Encorafenib Palbociclib Olaparib Ribociclib Abemaciclib Talazoparib Nivolumab Atezolizumab Pembrolizumab | 2 Years - | Peter MacCallum Cancer Centre, Australia | |
| A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer | NCT04188548 | Breast Cancer Advanced Breast... Metastatic Brea... Endometrial Can... | LY3484356 Abemaciclib Everolimus Alpelisib Trastuzumab Aromatase Inhib... Pertuzumab | 18 Years - | Eli Lilly and Company | |
| A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world Setting | NCT04967248 | Hormone Recepto... | Alpelisib Fulvestrant | 18 Years - | Novartis | |
| Managed Access Program to Provide Access to Alpelisib for Patients With Advanced Breast Cancer | NCT04473040 | HR+, HER2-, Adv... | alpelisib | 18 Years - 99 Years | Novartis | |
| Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer | NCT04544189 | Breast Neoplasm... | Alpelisib Fulvestrant Placebo | 18 Years - | Novartis | |
| Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation. | NCT05948943 | Lymphatic Malfo... | Alpelisib Placebo | 2 Years - | Novartis | |
| Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation. | NCT05948943 | Lymphatic Malfo... | Alpelisib Placebo | 2 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
